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RESUMO – As malformações glomuvenosas manifestam-se geralmente sob a forma de pápulas, placas ou nódulos azul-violáceos, 
dérmicos ou subcutâneos, e podem ser esporádicas ou hereditárias. Apresentamos o caso de uma mulher de 41 anos, referenciada 
para avaliação de um quadro de lesões cutâneas disseminadas, azuladas, com evolução desde a puberdade. O exame histopatoló-
gico foi compatível com o diagnóstico de malformações glomuvenosas. A história familiar de uma irmã com lesões semelhantes mo-
tivou o estudo genético do gene da glomulina na nossa doente, que revelou uma variante patogénica e possibilitou o diagnóstico de 
malformações glomuvenosas cutâneas disseminadas familiares. Malformações glomuvenosas únicas ou escassas, sintomáticas, são 
frequentemente submetidas a excisão cirúrgica, enquanto que outras modalidades terapêuticas têm sido reportadas no tratamento 
de lesões múltiplas, com resultados variáveis. A doente foi submetida a escleroterapia com polidocanol, resultando em melhorias 
sintomática e cosmética muito significativas após seis sessões, sem efeitos adversos e sem recorrência aos 6 meses.
PALAVRAS-CHAVE – Escleroterapia; Neoplasias da Pele; Tumor Glómico/genética; Tumor Glómico/tratamento.
Sclerotherapy in the Treatment of Familial Dissemi-
nated Cutaneous Glomuvenous Malformations: Case 
Report   
ABSTRACT – Glomuvenous malformations usually present as soft bluish-purple dermal or subcutaneous papules, nodules or plaques, 
and can occur as sporadic or inherited lesions. We present the case of a 41-year-old female, referred for evaluation of disseminated 
bluish lesions developing since puberty. Histopathology was consistent with the diagnosis of glomuvenous malformations. The history 
of a sister with similar lesions justified a genetic study of the glomulin gene that revealed a pathogenic mutational variant allowing the 
diagnosis of familial disseminated cutaneous glomuvenous malformations. Whereas surgical management is often used for symptoma-
tic solitary lesions of glomuvenous malformations, other treatment modalities have been reported for treatment of multiple lesions, with 
variable results. The patient underwent sclerotherapy with polidocanol and there were significant symptomatic and cosmetic improve-
ments after six sessions, with no adverse effects and no recurrence after 6 months.
KEYWORDS – Glomus Tumor/genetics; Glomus Tumor/therapy; Sclerotherapy; Skin Neoplasms.
 
INTRODUCTION
Glomuvenous malformations (GVM), also known as glo-
mangiomas, are benign abnormal vascular proliferations 
arising from glomus cells,1 which are considered modi-
fied smooth muscle cells of the glomus body, a specialized 
form of arteriovenous anatomosis involved in thermal and 
baroregulation.2,3 GVM are most often sporadic but familial 
forms exist, caused by mutations in the glomulin (GLMN) 
gene.1,4 Disseminated lesions are uncommon, representing 
less than 10% of all reported cases.5 We present a patient 
with multiple hereditary GVM who was successfully treated 
using sclerotherapy techniques.
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CASE REPORT
A 41-year-old female, with irrelevant medical history, 
presented to our department with multiple bluish-purple 
cutaneous lesions evolving since puberty, with a slow but 
sustained development of new lesions. There were no other 
related local or systemic manifestations. Her sister had si-
milar lesions, although with a more circumscribed pattern. 
On examination there were bluish-purple firm papulo-
nodules, ranging in size from 2 to 10 mm, distributed over 
the upper and lower limbs, trunk and face, but most nume-
rous on the right lumbar area (Fig. 1). Lesions were tender 
on palpation.
Keeping the possibilities of GVM, blue rubber bleb nevus 
syndrome (BRBNS) and venous malformation, an excisional 
biopsy of one of the lesions was performed, demonstrating 
clusters of dilated vascular channels lined by glomus cells 
(Fig. 2). These findings supported a diagnosis of GVM.
Attending to the family background, the patient un-
derwent mutational analysis for the GLMN gene (1p21-
22), which revealed heterozygosity for a pathogenic 
variant not previously reported in the literature – c.971dupT 
p.(Leu324Phefs*19). At this point the diagnosis of multiple 
familial GVM/familial disseminated cutaneous GVM was 
made.
The benignity of the diagnosis and prognosis were ex-
plained to the patient. Due to the associated pain and for 
cosmetic reasons, treatment of the most symptomatic lesions 
was decided. Surgical excision was not achievable because 
the lesions were multiple and disseminated. A literature re-
view showed many therapeutic options have been attempted 
in disseminated GVM, with variable and frequently unsatis-
factory results, but revealed sclerotherapy as a promising 
option. 
The patient underwent sclerotherapy with growing con-
centrations of polidocanol, starting from 0.5%, to minimize 
the risk of cutaneous ulcerations and pain. These possible 
adverse events were explained to the patient and a total 
number of sessions was not established – it would depend 
on the results after each session. The first step was to deli-
mitate the lesions to be treated in each session. The right 
lumbar cluster of lesions was the first to be treated, as these 
were the most exuberant and symptomatic, and the other 
foci were treated subsequently. Lesions were injected directly 
using a 30 gauge needle. Initially blood was drawn back to 
ensure intraluminal position of the needle and the sclerosant 
was injected slowly, inducing the swelling and mild blan-
ching of the lesion. After the injection of each lesion, cotton 
balls were applied and the area was compressed using a 
short stretch compression bandage. The patient was then 
instructed to maintain the compression for at least 36 hours.
A total of six sessions were performed, at 2-3 weeks in-
tervals. Polidocanol concentrations of 0.5% and 1% were 
used, as the satisfactory clinical response dismissed any 
further escalation. The average volume of sclerosant was 
0.5-0.8 mL per lesion per session. Smaller lesions were in-
jected once, but larger ones required 2 injections of sclero-
sant. This approach resulted in a significant improvement, 
with flattening of the lesions and a very satisfactory cosme-
tic result, but mostly, lesional pain neutralization, the main 
complaint of the patient (Fig. 3). The procedure was well 
tolerated, with a minor discomfort during and immediate-
ly after each session. Besides a residual hyperpigmentation 
that faded over the weeks after the treatment, there were 
no immediate or long-term complications and in particular 
there was no ulceration or scarring. The patient is under 
follow-up and there was no recurrence of lesions over trea-
ted sites after 6 months. First degree relatives were referred 
for genetic counseling.
DISCUSSION
GVM may either be acquired or inherited.4 The inheri-
tance pattern is believed to be autosomal dominant with in-
complete penetrance and variable expression. Heterozygous 
germline mutations in the GLMN gene on chromosome 
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Figure 1 - Grouped bluish-purple papulonodules on the right lumbar 
region. 
Figure 2 - Dilated vascular spaces lined by glomus cells (H&E, 200x). 
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1p21-22 have been found to contribute to the formation 
of GVM.1,6,7 In this case a new pathogenic variant, not pre-
viously reported in the literature, was detected, highlighting 
the familial predisposition for the disease. Like most of the 
pathogenic variants identified in this gene so far, this one 
caused the insertion of a premature termination codon.
GVM typically present as blue-to-purple papules or no-
dules, grouped and limited to a specific area, usually an ex-
tremity.5 Multiple GVM present as bluish nodules, anywhere 
from two to more than one hundred, and may be localized, 
segmental or disseminated over the entire body.8,9
Multiple GVM must be distinguished from BRBNS, due to 
the important risk of gastrointestinal hemorrhage associated 
with the latter: lack of mucosal and gastrointestinal involve-
ment and glomus cells on histopathology are distinguishing 
features of GVM.1
The prognosis for patients with GVM is excellent. Malig-
nant transformation is extremely rare and typically repre-
sents a locally infiltrative malignancy.5 Lesional size larger 
than 2 cm, rapid growth and deeper soft tissue involvement 
are clues to suspect malignant transformation.10 
Abstaining from therapy and regular observation may 
be an option in asymptomatic lesions, while the treatment of 
choice for symptomatic solitary GVM is surgical excision.8,11 
However this may not be feasible for multiple or large seg-
mental lesions8,12 and there is a possibility of recurrence 
even with complete surgical excision.11 Several therapeu-
tic modalities have been used for the treatment of multiple 
GVM, including sclerotherapy, argon and carbon dioxide 
laser therapy and electron-beam irradiation, with variable 
efficacy, recurrence rates and residual scarring.5,13
Sclerotherapy involves introduction of a sterile solution 
into the lumen of a blood vessel or a vascular lesion to in-
duce permanent endofibrosis and ablation. Sclerotherapy 
has been attempted with polidocanol, sodium tetradecyl 
sulfate, hypertonic saline and absolute alcohol, among other 
agents.5 Potential complications of sclerotherapy include ne-
crosis and ulceration, hyperpigmentation and telangiectatic 
matting, localized hypertrichosis, trombophlebitis and loca-
lized paresthesia, and these adverse effects are recognized 
to be concentration dependent.13
Sclerotherapy resulted in significant symptomatic and 
cosmetic improvements in our patient, with no complica-
tions, and at 6 months post-procedure no recurrence of the 
treated lesions was noticed. A cautious approach, starting 
with low concentrations of the sclerosant and increasing ac-
cording to the response is advisable to avoid the risk of cuta-
neous ulceration. Given the scarcity of good options to treat 
multiple GVM, our experience corroborates previous reports 
that sclerotherapy appears to be an effective and safe me-
thod for treatment of disseminated lesions.
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